The Inhibitory Effect of Sorafenib Combined with Cisplatin on Gastric Cancer SGC7901 Cells

Objective: To investigate the inhibitory effect of sorafenib combined with cisplatin on proliferation of gastric cancer cells and the underlying mechanisms.Methods: SGC7901 cells were treated with sorafenib,cisplatin or sorafenib combined with cisplatin.The cell viability was examined by MTT assay.Apoptosis was detected by flow cytometry.The expression of ERK and pERK were determined by western blot.Results: 1.Sorafenib and cisplatin,used alone or in combination,could significantly inhibit the proliferation of SGC7901 cells time-and dose-dependently.2.The combination of sorafenib and cisplatin markedly sensitized cells to drug-induced apoptosis and suppressed cell proliferation.3.The phosphorylation of ERK was decreased in cells treated with sorafenib.The expression of p-ERK was even dramatically reduced in cells treated with sorafenib combined with cisplatin.Conclusions: The synergistic effect of sorafenib and cisplatin was found in inhibiting cell proliferation and inducing cell apoptosis of gastric cancer cells.Those could partially attribute to the inactivation of Raf/MEK/ERK signaling pathway.